ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice

2010
Authors
Yalcin, SafakMarinković, Dragan

Mungamuri, Sathish Kumar

Zhang, Xin
Tong, Wei

Sellers, Rani
Ghaffari, Saghi
Article (Published version)

Metadata
Show full item recordAbstract
Reactive oxygen species (ROS) participate in normal intracellular signalling and in many diseases including cancer and aging, although the associated mechanisms are not fully understood. Forkhead Box O (FoxO) 3 transcription factor regulates levels of ROS concentrations, and is essential for maintenance of hematopoietic stem cells. Here, we show that loss of Foxo3 causes a myeloproliferative syndrome with splenomegaly and increased hematopoietic progenitors (HPs) that are hypersensitive to cytokines. These mutant HPs contain increased ROS, overactive intracellular signalling through the AKT/mammalian target of rapamycin signalling pathway and relative deficiency of Lnk, a negative regulator of cytokine receptor signalling. In vivo treatment with ROS scavenger N-acetyl-cysteine corrects these biochemical abnormalities and relieves the myeloproliferation. Moreover, enforced expression of Lnk by retroviral transfer corrects the abnormal expansion of Foxo3(-/-) HPs in vivo. Our combined re...sults show that loss of Foxo3 causes increased ROS accumulation in HPs. In turn, this inhibits Lnk expression that contributes to exaggerated cytokine responses that lead to myeloproliferation. Our findings could explain the mechanisms by which mutations that alter Foxo3 function induce malignancy. More generally, the work illustrates how deregulated ROS may contribute to malignant progression. The EMBO Journal (2010) 29, 4118-4131. doi: 10.1038/emboj.2010.292; Published online 26 November 2010
Keywords:
FoxO / Lnk / mTOR / myeloproliferation / ROSSource:
Embo Journal, 2010, 29, 24, 4118-4131Publisher:
- Wiley, Hoboken
Funding / projects:
- National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 DK077174]
- American Cancer Society Research Scholarship [RSG LIB-110480]
- Black Family Stem Cell Institute
- Roche Foundation for Anemia Research (RoFAR)
- United States Department of Health & Human Services, National Institutes of Health (NIH), National Heart Lung & Blood Institute (NHLBI) [R01HL095675, R01HL110806]
- United States Department of Health & Human Services, National Institutes of Health (NIH), National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK077174]
DOI: 10.1038/emboj.2010.292
ISSN: 0261-4189
PubMed: 21113129
WoS: 000285407200008
Scopus: 2-s2.0-78650302424
Collections
Institution/Community
rFASPERTY - JOUR AU - Yalcin, Safak AU - Marinković, Dragan AU - Mungamuri, Sathish Kumar AU - Zhang, Xin AU - Tong, Wei AU - Sellers, Rani AU - Ghaffari, Saghi PY - 2010 UR - http://rfasper.fasper.bg.ac.rs/handle/123456789/377 AB - Reactive oxygen species (ROS) participate in normal intracellular signalling and in many diseases including cancer and aging, although the associated mechanisms are not fully understood. Forkhead Box O (FoxO) 3 transcription factor regulates levels of ROS concentrations, and is essential for maintenance of hematopoietic stem cells. Here, we show that loss of Foxo3 causes a myeloproliferative syndrome with splenomegaly and increased hematopoietic progenitors (HPs) that are hypersensitive to cytokines. These mutant HPs contain increased ROS, overactive intracellular signalling through the AKT/mammalian target of rapamycin signalling pathway and relative deficiency of Lnk, a negative regulator of cytokine receptor signalling. In vivo treatment with ROS scavenger N-acetyl-cysteine corrects these biochemical abnormalities and relieves the myeloproliferation. Moreover, enforced expression of Lnk by retroviral transfer corrects the abnormal expansion of Foxo3(-/-) HPs in vivo. Our combined results show that loss of Foxo3 causes increased ROS accumulation in HPs. In turn, this inhibits Lnk expression that contributes to exaggerated cytokine responses that lead to myeloproliferation. Our findings could explain the mechanisms by which mutations that alter Foxo3 function induce malignancy. More generally, the work illustrates how deregulated ROS may contribute to malignant progression. The EMBO Journal (2010) 29, 4118-4131. doi: 10.1038/emboj.2010.292; Published online 26 November 2010 PB - Wiley, Hoboken T2 - Embo Journal T1 - ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice EP - 4131 IS - 24 SP - 4118 VL - 29 DO - 10.1038/emboj.2010.292 ER -
@article{ author = "Yalcin, Safak and Marinković, Dragan and Mungamuri, Sathish Kumar and Zhang, Xin and Tong, Wei and Sellers, Rani and Ghaffari, Saghi", year = "2010", abstract = "Reactive oxygen species (ROS) participate in normal intracellular signalling and in many diseases including cancer and aging, although the associated mechanisms are not fully understood. Forkhead Box O (FoxO) 3 transcription factor regulates levels of ROS concentrations, and is essential for maintenance of hematopoietic stem cells. Here, we show that loss of Foxo3 causes a myeloproliferative syndrome with splenomegaly and increased hematopoietic progenitors (HPs) that are hypersensitive to cytokines. These mutant HPs contain increased ROS, overactive intracellular signalling through the AKT/mammalian target of rapamycin signalling pathway and relative deficiency of Lnk, a negative regulator of cytokine receptor signalling. In vivo treatment with ROS scavenger N-acetyl-cysteine corrects these biochemical abnormalities and relieves the myeloproliferation. Moreover, enforced expression of Lnk by retroviral transfer corrects the abnormal expansion of Foxo3(-/-) HPs in vivo. Our combined results show that loss of Foxo3 causes increased ROS accumulation in HPs. In turn, this inhibits Lnk expression that contributes to exaggerated cytokine responses that lead to myeloproliferation. Our findings could explain the mechanisms by which mutations that alter Foxo3 function induce malignancy. More generally, the work illustrates how deregulated ROS may contribute to malignant progression. The EMBO Journal (2010) 29, 4118-4131. doi: 10.1038/emboj.2010.292; Published online 26 November 2010", publisher = "Wiley, Hoboken", journal = "Embo Journal", title = "ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice", pages = "4131-4118", number = "24", volume = "29", doi = "10.1038/emboj.2010.292" }
Yalcin, S., Marinković, D., Mungamuri, S. K., Zhang, X., Tong, W., Sellers, R.,& Ghaffari, S.. (2010). ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. in Embo Journal Wiley, Hoboken., 29(24), 4118-4131. https://doi.org/10.1038/emboj.2010.292
Yalcin S, Marinković D, Mungamuri SK, Zhang X, Tong W, Sellers R, Ghaffari S. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. in Embo Journal. 2010;29(24):4118-4131. doi:10.1038/emboj.2010.292 .
Yalcin, Safak, Marinković, Dragan, Mungamuri, Sathish Kumar, Zhang, Xin, Tong, Wei, Sellers, Rani, Ghaffari, Saghi, "ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice" in Embo Journal, 29, no. 24 (2010):4118-4131, https://doi.org/10.1038/emboj.2010.292 . .